By: Praveen Vuppu Jyothi, Forward Deployed Engineer, Improzo
Pharma does not have an LLM problem. It has a context problem. Over the past two years, pharmaceutical companies have tested generative AI across search, summarisation, content creation and employee productivity. These experiments have shown that large language models can be highly effective at understanding and generating language. But as organisations move from pilots to enterprise-scale adoption, a more important question is emerging: can AI understand how pharmaceutical decisions are made?
AI will need to move beyond summary or basic content generation because high-value pharma workflows are rarely simple information-retrieval tasks. They depend on scientific context, commercial rules, data relationships, governance requirements and role-specific interpretation. The same physician, account, patient population or dataset can mean very different things depending on whether the user sits in medical affairs, commercial operations, market access or forecasting. On top of that, these workflows are rarely written down and require a new way to capture them.
What makes AI “domain-native” in pharma?
Domain-native AI is designed around the terminology, data structures, workflows and decision logic of the pharmaceutical industry. It must understand not only what a user is asking, but why they are asking it, which data matters, what rules apply, and how the answer should be interpreted. This requires practitioner experience coupled with LLM model tuning.
Consider a field leader asking, “Which physicians should we prioritise next month?” A generic chatbot may summarise available information. A domain-native system should be able to reason across prescribing behaviour, patient opportunity, speciality, affiliations, engagement history, formulary dynamics, territory rules, and approved business logic before making a recommendation. This design is not just between a weaker and stronger chatbot. It is between language understanding and decision understanding.
“The constraint in life sciences is rarely access to information. It is understanding what that information means in a particular scientific, commercial or regulatory context. AI becomes much more valuable when that context is part of the system rather than something the user has to explain with every prompt.”
—Jane Urban, former VP, Takeda Pharmaceuticals
Why generic AI often struggles in pharma
The first challenge is fragmentation. A single business question may require information from CRM platforms, claims, patient services, medical interactions, formulary data, digital engagement, market research and third-party sources. Access alone is not enough; AI must understand how these sources relate and which signals matter most.
The second challenge is domain-specific reasoning. Terms such as NRx, TRx, KOL engagement, line of therapy (LOT), formulary restriction and next-best action cannot always be interpreted correctly without the workflow around them.
The third challenge is governance and transparency. In a regulated environment, users need to understand where an answer came from, what data was used, and whether the recommendation follows the appropriate business rules and access controls.
For AI to move into core pharma workflows, four capabilities become critical:
- Pharmaceutical semantic and workflow understanding;
- Integration across structured and unstructured data;
- Traceability back to underlying evidence; and
- Embedded governance, access controls and business rules.
The next phase of AI adoption is likely to be less about standalone chat interfaces and more about domain-specific agents embedded within operational workflows.
The shift from chatbots to domain-specific agents
The next phase of AI adoption is likely to be less about standalone chat interfaces and more about domain-specific agents embedded within operational workflows. A medical affairs agent could synthesise MSL interactions and identify emerging scientific themes. A forecasting agent could investigate an unexpected variance and test likely drivers. A commercial intelligence agent could combine market signals, account history and approved prioritisation logic to guide field activity. The balance between frontier models, natural language processing and rules-based coding is critical to get these agents tuned into those needs.
In each case, the conversational interface is only the visible layer. The real value lies underneath it: domain context, connected data, workflow logic and governance. For pharma leaders, the strategic question is therefore shifting from “Which generative AI model should we adopt?” to something more consequential:
How do we build AI that understands how our business actually works?

Praveen Vuppu Jyothi, Forward Deployed Engineer, Improzo


